Eli Lilly (NYSE: LLY ) , like many of its peers in the pharma industry, continues to battle the effects of the patent cliff. Two of its three top-selling products will lose exclusivity this year, but there is one jewel in its crown that investors don't need to worry about. In this video, health care analyst Max Macaluso dives into this drug's clinical use and growth.
Can Lilly defeat the patent cliff?
Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.